Partner Headlines - BMY

  1. Bristol-Myers scores again

    IBD
  2. It's A Big Weekend For Biotech

    Benzinga
  3. Bristol's Opdivo Scores Again Against Lung Cancer

    IBD
  4. Bristol's Opdivo Scores Again Against Lung Cancer

    IBD
  5. Bristol-Myers Up Big After Drug Study Stopped Early

    Benzinga
  6. AstraZeneca's Onglyza Ups Risk Of Death, FDA Says

    IBD
  7. Benzinga's M&A Chatter for Monday April 13, 2015

    Benzinga
  8. Bristol-Myers Squibb Canada Announces Hepatitis C Cure Rate of ...

    Benzinga
  9. UPDATE: USDA Approves Supplimental Biologics License

    Benzinga
  10. USDA Accepts Supplemental Biologics License Application for Yervoy ...

    Benzinga
  11. Bristol Myers Reports Data Supporting Clinical Development Of ...

    Benzinga
  12. Biotech Pharmacyclics Spikes On Buyout Rumors

    IBD
  13. Bristol-Myers Squibb Launches Phase III Trial Of HIV Drug

    Benzinga
  14. Lannett Joins Big-Game Hunt For Drugmaker Acquisitions

    IBD
  15. Bristol-Myers goes for the gut

    IBD
  16. Drugmaker Mylan Takes Part In Pharma Feeding Frenzy

    IBD
  17. Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals ...

    GuruFocus
  18. Pharma M&A: Bristol-Myers, Valeant Make Deals

    IBD
  19. Morning Market Gainers

    Benzinga
  20. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  21. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  22. Strong Dollar Weakens Views

    IBD
  23. Drugmakers Warn On Dollar

    IBD
  24. Strong Dollar Pins U.S. Corporate Earnings Outlook

    IBD
  25. Drug Firms Report Good Q4, But Outlook Cloudy

    IBD
  26. Strong Dollar Means Flabby Outlook For Some Overseas

    IBD
  27. Bristol, Pfizer, Novartis Forecasts Face FX Pressures

    IBD
  28. Tuesday Morning Movers: Microsoft, Procter & Gamble Tumble Following ...

    Benzinga
  29. UPDATE: Bristol-Meyers Squibb Posts Upbeat Q4 Results, Issues ...

    Benzinga
  30. Earnings Scheduled For January 27, 2015

    Benzinga
  31. Pharmaceuticals Sector To See High Voltage Action in 2015

    GuruFocus
  32. 3 High-Flying Health Care Stock IPOs To Watch In 2015

    IBD
  33. BRISTOL-MYERS SQUIBB

    IBD
  34. Bristol-Myers Squibb Names Caforio CEO, Andreotti To Become Chairman

    Benzinga
  35. Feeling Good With This Med Company

    GuruFocus
  36. 10 Biotech Stories You Might've Missed This Week

    Benzinga
  37. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  38. Celgene Outlook Is Upbeat

    IBD
  39. Celgene, Bristol-Myers Cancer Drug News Lifts Stocks

    IBD
  40. Bristol-Myers Hits 14-Year High On Cancer Drug Trial

    IBD
  41. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  42. Morning Market Gainers

    Benzinga
  43. Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2 ...

    Benzinga
  44. What Investors Should Expect From Portola Pharmaceutical's Upcoming ...

    Benzinga
  45. Jim Cramer Advises His Viewers On Wynn Resorts And Second Sight ...

    Benzinga
  46. Bristol-Myers Squibb and California Institute for Biomedical ...

    Benzinga
  47. 5 Biotech Stocks With Big News Due In January

    IBD
  48. FDA's OKs may prescribe hits

    IBD
  49. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  50. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD
  51. Celgene drug could gain share

    IBD
  52. Celgene's Abraxane Succeeds In Early Breast Cancer

    IBD
  53. Merck's Keytruda Might Treat Virulent Breast Cancer

    IBD
  54. US Stock Futures Edge Lower Ahead Of Federal Budget

    Benzinga
  55. T Rowe Price's Top Stakes for the Third Quarter

    GuruFocus
  56. I think Zimmer Will Outperform S&P 500 Performance

    GuruFocus
  57. Avanir Stock Jumps On $3.5 Billion Otsuka Buyout

    IBD
  58. A Buy Recommendation From Absolute Valuation Model to Bristol-Myers ...

    GuruFocus
  59. Screening Pharma Stocks Amid Turnaround

    YCharts
  60. Incyte Building Blockbuster Drug One Disease At A Time

    IBD
  61. Blackhill Bets Almost Half of Portfolio on Williams-Sonoma

    GuruFocus
  62. Merck Down On Hepatitis C Data; Gilead Rises

    IBD
  63. A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio

    GuruFocus
  64. Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb ...

    Benzinga
  65. Lung cancer drug promising

    IBD
  66. Bristol-Myers Lung-Cancer Drug Boosts Survival

    IBD
  67. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line ...

    Benzinga
  68. Eliquis revives Bristol-Myers

    IBD
  69. Bristol-Myers Beats Q3 Views As Eliquis Revives

    IBD
  70. Stocks Flat In Mixed Volume; Amazon.com Weighs On Techs

    IBD
  71. UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates

    Benzinga
  72. Stock Futures Aim For Flat Open; Amazon.com Crumples On Q3 Miss

    IBD
  73. #PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets

    Benzinga
  74. Earnings Scheduled For October 24, 2014

    Benzinga
  75. Must Watch Stocks for Today

    Benzinga
  76. Stocks Rebound; Amazon.com Slides After Hours

    IBD
  77. Drug ETFs Attractive Buys On Pullback

    Benzinga
  78. Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, ...

    GuruFocus
  79. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  80. Apple Leads the Charge as Earnings Season Heats Up

    FoxBusiness
  81. The Six Types of Winning Stocks

    GuruFocus
  82. Markets Debut Week On Negative Note; S&P 500 Falls Through Key ...

    Benzinga
  83. Merck to release hep C data

    IBD
  84. Merck, Bristol, Arrowhead Prep Hepatitis Studies

    IBD
  85. Salix, Actavis Among Big Cap Pharmas In Merger Mambo

    IBD
  86. Bristol-Myers pulls FDA filing

    IBD
  87. Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo

    IBD
  88. Bristol-Myers Squibb Statement About Asunaprevir In The US, WIthdraws ...

    Benzinga
  89. 2 Mutual Funds Holding Hospital Stocks

    Benzinga
  90. NeurOp Receives Milestone Payment As Bristol-Myers Squibb Nominates ...

    Benzinga
  91. Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly ...

    Benzinga
  92. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD
  93. Gilead OKs Generic Sovaldi To Expand Global Access

    IBD
  94. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. ...

    Benzinga
  95. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD
  96. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  97. Booming Biotech Market Benefits REIT BioMed Realty

    IBD
  98. Bristol-Myers: Absolute Valuation Model versus Relative Valuation ...

    GuruFocus
  99. Bristol-Myers Drug Gets OK

    IBD
  100. Markets Little Changed In Low Volume And Slow News Ahead Of Long ...

    Benzinga
Trading Center